Roche signs definitive share purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases
09 Septiembre 2021 - 12:00AM
Roche signs definitive share purchase agreement with long-term
partner TIB Molbiol to expand PCR-test portfolio in the fight
against new infectious diseases
- Roche to acquire the TIB
Molbiol Group with the expectation to
close in fourth quarter of 2021
- TIB Molbiol excels in
ultra-rapid assay development for emerging infectious disease,
strongly demonstrated during the COVID-19 pandemic
- The acquisition enables Roche to further expand the
portfolio of currently over 45 CE-IVD assays and more than 100
research use assays on Roche`s
LightCycler PCR instruments
Basel, 09 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY)
today announced that it has signed a definitive share purchase
agreement to acquire 100% of the outstanding shares of the TIB
Molbiol Group. Closing of the transaction is subject to customary
conditions and is expected in the fourth quarter of 2021.
The acquisition of the TIB Molbiol Group will enhance Roche’s
broad portfolio of molecular diagnostics solutions with a wide
range of assays for infectious diseases, such as the identification
of SARS-CoV-2 variants. TIB Molbiol’s comprehensive portfolio of
over 45 CE-IVD assays and more than 100 research use assays are
already today available on Roche’s large installed base of
LightCycler PCR systems and MagNA Pure sample preparation
systems.
The two companies have collaborated for more than 20 years to
rapidly address critical healthcare needs including biological
threats, such as SARS, anthrax, avian influenza virus H5N1, MERS,
the novel influenza virus H1N1 swine, Ebola virus, Zika virus and
most recently, SARS-CoV-2 virus and its variants. For example, in
2001 with anthrax and 2003 with SARS-CoV1, TIB Molbiol demonstrated
their ability to develop PCR assays for the detection of new
pathogens within days.
“With this acquisition, we can expand our offering of tests of
existing pathogens and our response to emerging pathogens and
potential health threats,” said Thomas Schinecker, CEO Roche
Diagnostics. “At the onset of the COVID-19 pandemic, our
collaboration provided the first research-use-only SARS-CoV-2
detection test that was provided in January 2020, only days after
the new coronavirus was first sequenced. Together, we can further
improve patient outcomes with innovative diagnostic solutions that
alleviate healthcare costs.”
“We are very happy to join the Roche Group,” said Olfert Landt,
CEO and founder of TIB Molbiol. “We have been collaborating for two
decades and have spearheaded innovation in the molecular
diagnostics industry as partners. We are looking forward to
contributing to the strong network of Roche Diagnostics.”
About TIB MolbiolTIB Molbiol
is a biotech company that has supplied the global market with
reagents for research and medical diagnostics for over 30 years. As
manufacturer of custom oligonucleotides the company partnered in
the development of molecular diagnostics and built a broad
portfolio of diagnostic assays, in particular for inherited genetic
as well as somatic mutation testing, quantitative assays for
haematology and transplantation medicine. The majority of assays
are used to test for infectious diseases. They are available as
modular kits, enabling the creation of symptomatic panels by
combining assays, including emerging pathogens. To support
customers performing human genotyping, TIB Molbiol provides custom
made LightSNiP assays for SNP analysis. TIB Molbiol is
headquartered in Berlin (Germany) and has local representations in
Australia, Colombia, Italy, Spain and the US.About
RocheRoche is a global pioneer in pharmaceuticals and
diagnostics focused on advancing science to improve people’s lives.
The combined strengths of pharmaceuticals and diagnostics, as well
as growing capabilities in the area of data-driven medical insights
help Roche deliver truly personalised healthcare. Roche is working
with partners across the healthcare sector to provide the best care
for each person.
Roche is the world’s largest biotech company, with truly
differentiated medicines in oncology, immunology, infectious
diseases, ophthalmology and diseases of the central nervous system.
Roche is also the world leader in in vitro diagnostics and
tissue-based cancer diagnostics, and a frontrunner in diabetes
management. In recent years, Roche has invested in genomic
profiling and real-world data partnerships and has become an
industry-leading partner for medical insights.
Founded in 1896, Roche continues to search for better ways to
prevent, diagnose and treat diseases and make a sustainable
contribution to society. The company also aims to improve patient
access to medical innovations by working with all relevant
stakeholders. More than thirty medicines developed by Roche are
included in the World Health Organization Model Lists of Essential
Medicines, among them life-saving antibiotics, antimalarials and
cancer medicines. Moreover, for the twelfth consecutive year, Roche
has been recognised as one of the most sustainable companies in the
Pharmaceuticals Industry by the Dow Jones Sustainability Indices
(DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active
in over 100 countries and in 2020 employed more than 100,000 people
worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and
posted sales of CHF 58.3 billion. Genentech, in the United States,
is a wholly owned member of the Roche Group. Roche is the majority
shareholder in Chugai Pharmaceutical, Japan. For more information,
please visit www.roche.com.
All trademarks used or mentioned in this release are protected
by law.Roche Group Media RelationsPhone: +41 61
688 8888 / e-mail: media.relations@roche.com
Dr. Nicolas
DunantPhone: +41 61 687 05 17 |
Patrick
BarthPhone: +41 61 688 44 86 |
Dr. Barbara von
SchnurbeinPhone: +41 61 687 89 67 |
Karsten
KleinePhone: +41 61 682 28 31 |
Nina
MählitzPhone: +41 79 327 54 74 |
Nathalie
MeetzPhone: +41 61 687 43 05 |
Roche
Investor Relations |
|
Dr. Karl
MahlerPhone: +41 61 68-78503e-mail: karl.mahler@roche.com |
Jon Kaspar
BayardPhone: +41 61 68-83894e-mail:
jon_kaspar.bayard@roche.com |
Dr. Sabine
BorngräberPhone: +41 61 68-88027e-mail:
sabine.borngraeber@roche.com |
Dr. Bruno
EschliPhone: +41 61 68-75284e-mail:
bruno.eschli@roche.com |
Dr. Birgit
MasjostPhone: +41 61 68-84814e-mail: birgit.masjost@roche.com |
Dr. Gerard
TobinPhone: +41 61 68-72942e-mail: gerard.tobin@roche.com |
|
|
Investor
Relations North America |
|
Loren KalmPhone:
+1 650 225 3217e-mail: kalm.loren@gene.com |
|
- 09092021_MR_TIB Molbiol_en
Roche (LSE:0QQ6)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Roche (LSE:0QQ6)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024